Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by retiredcopon Jun 14, 2018 7:20pm
89 Views
Post# 28175165

More on exosomes

More on exosomes 

SCIENTISTS: THIS CELL PART COULD BE KEY TO STOPPING THE SPREAD OF ALZHEIMER’S DISEASE

BY DANA DOVEY ON 6/14/18 AT 4:30 PM
 
TECH & SCIENCEALZHEIMER'S DISEASE
Scientists believe that buildup of a brain protein called amyloid beta is the root of Alzheimer’s disease, but exactly how this disease spreads throughout the brain remains unclear. Now, new research believes it may have found the answer, suggesting that a cell previously thought to play a role in waste removal is actually the key to the spread of Alzheimer’s in the brain.
 
The study, published online in Acta Neuropathologica, used brain samples from deceased patients with Alzheimer’s disease and control patients who died with a healthy brain. They looked specifically at parts of the cell called exosomes. These cell parts are small membrane-covered droplets that help to remove cell waste products, a press release reported. However, closer examination revealed the cell part may also play an important part in Alzheimer’s disease ability to spread throughout the brain.
 
For their research, the team noted this cell part was physically capable of transporting amyloid beta from one cell to another. To observe this, researchers took cells from Alzheimer's disease patients and watched as they absorbed exosomes and then passed amyloid beta to new cells.

Bullboard Posts